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Introduction: Despite newer treatment modalities, few patients with non-small cell lung cancer in stages IIIB and IV
survive the median of one year. We present four patients with non-small cell lung cancer treated with an adjuvant
therapy with cascade primed immune cells. The in vitro stimulated expression of cancer information on the patients’
monocytes matures and activates T lymphocytes to destroy cancer cells. The cascade primed immune cell therapy
significantly improved the quality of life and the lifespan of all four patients; thus far, three patients survived 40, 55
and 120 months, respectively; and one patient died 39 months after diagnosis.
Case presentation: Patient 1, stage IV (T4N2M1): The adenocarcinoma of the 67-year-old German Caucasian
man infiltrated into the mediastinal lymph nodes and iliosacral bones. Chemotherapy modalities were started
immediately after diagnosis of cancer, and cascade primed immune cell therapy one year later. The patient survived
39 months.
Patient 2, stage IV (T3N3M1a): The 62-year-old German Caucasian woman presented with adenocarcinoma of the
lower lobe with infiltrated lymph nodes of the mediastinum and malignant pleural effusion. Chemotherapy,
radiation and the cascade primed immune cell therapy were administered together. The patient is still alive after
40 months.
Patient 3, stage IIIB (T4N1-2M0): The 75-year-old German Caucasian woman presented with an undifferentiated
tumor and a separate tumor nodule in the ipsilateral lobe. The patient received only cascade primed immune cell
therapy after tumor resection and has survived for the last 55 months.
Patient 4, pancoast tumor (IIIB, T3N3M0): The 77-year-old German Caucasian man presented with an undifferentiated
tumor that infiltrated the lymph nodes, the clavicle, one rib and the plexus brachialis. In addition to chemotherapy
and radiation, cascade primed immune cells were administered every weekday for one year. After four months, no
living tumor cell was detected in the resected lung, the lymph nodes or the bone material. The patient is still alive
after 120 months.
Conclusions: The novel adoptive cell therapy with cascade primed immune cells significantly increased the survival
rate and maintained the quality of life for four patients with non-small cell lung cancer in stages IIIB and IV. Our
findings indicate that tumor resection, chemotherapy and radiation appear to support the cascade primed immune
cell therapy.* Correspondence: professor-wank@muenchen-mail.de
Immunotherapy Research Center, Pettenkoferstrasse 8, 80336 München,
Germany
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The interest in adoptive cell therapy (ACT) is continu-
ously growing for three reasons. First, Rosenberg et al. re-
ported convincing clinical results of ACT in patients with
tumor-infiltrating lymphocytes (TIL) who were treated for
melanoma [1]; and Takayama et al. reported their findings
for the treatment of liver cancer [2]. Second, in solid can-
cers, particularly in non-small cell lung cancer (NSCLC),
chemotherapy and radiation as well as newer modalities
achieve only a modest prolongation of survival time.
Third, this modest prolongation of survival is accompan-
ied by severe side effects that often heavily affect the qual-
ity of the patient’s shortened life. In ACT, two strategies
are most often used to stimulate and armour autologous
immune cells against cancer cells. One strategy is the
in vitro activation of T lymphocytes, which is based on the
fact that the T cells in malignant tumors recognize the
cancer cells but they do not destroy the cancer. As de-
scribed by Rosenberg et al., such TIL have been isolated,
resuscitated and amplified in vitro and subsequently in-
fused into the patients [1]. Another strategy employs the
patient’s dendritic cells, which are prepared in vitro with
different methods to express cancer peptides that can acti-
vate the naïve/resting T lymphocytes in vivo [3]. The cas-
cade primed immune (CAPRI) cell method uses elements
of both strategies.
Antigen-presenting cells (APC) internalize, process and
present foreign and autologous proteins; however, until re-
cently, it was not considered that APC could supply infor-
mation about autologous cancer proteins. If T lymphocytes
were activated with OKT3 antibodies in peripheral blood
mononuclear cell (PBMC) bulk cultures, they stimulate the
processing and the presentation of tumor-immunogenic
information. These stimulated monocytes could mature
autologous naïve/resting lymphocytes to cytotoxic effector
cells. In another published study, we demonstrated that ac-
tivated monocytes differentiated naïve/resting T lympho-
cytes to potent cancer-destructing effector T cells in vitro,
which significantly prolonged the lifespan of patients with
breast cancer [4]. In this study, we describe the successful
life prolongation of four patients with NSCLC in stages
IIIB and IV, who were treated with the CAPRI cells in
combination with surgical intervention and/or chemother-
apy and radiation.
All steps of the cell preparations, including the final
therapy (the treatment attempts), were controlled by a
medical doctor (RW). In Germany, treatment attempts
with new modalities are permitted if they are performed
on the authority of a medical doctor [4]. An institutional
review was not required. Patients were informed about
the experimental nature of the approach, and the ethics
recommendations of Helsinki along with subsequent
amendments of Tokyo 1975, Hong Kong 1989 and
Somerset West 1996 were followed.Case presentation
Patient 1
Oncological diagnosis
The 67-year-old German Caucasian man presented with
a tumor of the upper lung lobe that infiltrated the
mediastinum and the mediastinal lymph nodes, and
with metastases of the iliosacral bones. Evaluations of
the tumor size (T4), regional lymph node involvement
(N2) and distant metastases (M1) (T4N2M1) led to a
diagnosis of NSCLC in stage IV. A histological analysis
revealed adenocarcinoma. Locoregional progress was
seen 10 months after diagnosis (AD), malignant pleural
effusion 12 months AD, locoregional progress and
suspicion of brain metastases 20 months AD, tumor in-
filtration of the thorax walls and malignant pleural effu-
sion 32 months AD.
Therapy
Therapy was started immediately with injections of the
biphosphonate zoledronate and a combined chemother-
apy with paclitaxel, carboplatin and sorafenib (Figure 1).
The combined modality was stopped two months AD
because of diarrhea, vomiting, progressive weakness and
tumor growth. Sorafenib was continued and stopped 10
months AD because the disease progressed. Docetaxel
was started 12 months AD and stopped 15 months AD
because of paravasate application and leg edema despite
a marginal tumor reduction. Pemetrexed was started 20
months AD and stopped after one round because of the
same side effects. Two brain metastases were irradiated
with the gamma knife (20Gy/22Gy) two weeks later.
Treatment with the tyrosine kinase inhibitor erlotinib
was started 21 months AD and stopped after six months
because of leg edema, nose bleeding and peripheral neu-
ropathies. The latter condition was treated with gaba-
pentin unsuccessfully. A malignant pleural effusion was
drained 25 months AD; irradiation of the right spina
iliaca superior (35Gy) and an infusion of two red cell
concentrates were conducted because of chemotherapy-
associated anemia 29 months AD. A therapy with vino-
relbine was started 32 months AD and continued until
34 months AD (Figure 1).
ACT with the CAPRI cells started 12 months AD.
Three months after the CAPRI cell therapy, a marginal
reduction of the tumor was noticed in the computed
tomography (CT) scan. The patient survived 39 months;
over a period of 26 months he received, twice weekly,
268 injections comprising 60 to 80 million CAPRI cells,
two-thirds intravenously, one-third intracutaneously. The
cell donations were occasionally interrupted for a week
during the patient’s hospitalization. The CAPRI cell ther-
apy was hampered not only by the low leucocyte count
but also by the low quality of the immune cells. The pa-
tient survived 39 months.
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PATIENT 1
D = day of diagnosis
CH I = chemotherapy I: paclitaxel, carboplatin,
CH II = chemotherapy II: docetaxel,
CH III = chemotherapy III: pemetrexed,
CH IV = chemotherapy IV: vinorelbin,
RAD I = radiation I: brain metastases with gamma knife 20/22Gy,
RAD II = radiation II: spina iliaca superior 35Gy.
Figure 1 Survival time and therapeutic modalities of four patients with non-small cell lung cancer. Shown are months of survival after
diagnosis and therapeutic modalities in chronological order. CAPRI, cascade primed immune.
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Oncological diagnosis
The 62-year-old German Caucasian woman presented
with a nonresectable adenocarcinoma of the right lower
lobe with infiltrated lymph nodes of the mediastinum
and malignant pleural effusion, staged by tumor size and
dissemination (T3N3M1a) as IV.
The first CT scan 12 months AD showed a stable dis-
ease; a positron emission tomography/computed tom-
ography (PET/CT) scan 20 months AD exhibited a
marginal but definite progression of the disease, disinte-
gration of the central lymph nodes without enlarge-
ment, pleural effusion but no distant metastases. A
PET/CT scan 26 months AD, performed because of
swallowing difficulties, revealed an enlarged lymph node
that had caused a severe obstruction of the esophagus,
which required treatment with a stent. A histological
analysis revealed tumor infiltration, which had caused
the lymph node enlargement. Neither a second radi-
ation nor chemotherapy was performed.
Therapy
The patient received a combined treatment of radiation
and chemotherapy for three months starting two weeks
AD. Four cycles of cisplatin and pemetrexed were ad-
ministered together with a total of 64Gy.
ACT with the CAPRI cells started after radiation and
chemotherapy, that is, three months AD (Figure 2). In
the first six months, the patient received 40 to 60 million
CAPRI cells twice weekly; after improvement of the cell
count, the patient received 80 million CAPRI cells twiceweekly, two-thirds intravenously, one-third intracutane-
ously, with a total of 260 injections over a period of
35 months. The growing pleural effusion, diagnosed by
PET/CT scan 26 months AD, was first treated for several
months with thoracentesis and later successfully com-
bined with thoracic CAPRI cell injections eight times
using 100 to 300 million immune cells. After the first
thoracic injection of 300 million CAPRI cells, the patient
felt very weak and had a low-grade fever for two days.
Consequently, the dose of CAPRI cells was reduced to
100 million, which was well tolerated. The patient is still
alive after 40 months (Figure 2).Patient 3
Oncological diagnosis
The 75-year-old German Caucasian woman presented
with an undifferentiated tumor ‘resembling’ a squamous
cell carcinoma of the upper lobe and a separate tumor
nodule in the ipsilateral tumor lobe (T4N1-2M0, stage
IIIB). The PET/CT scan restaging each year had shown
no suspicious growth of the tumor until now.Therapy
The patient refused chemotherapy or radiation but agreed
to surgery. The upper lobe was resected two months AD,
the middle lobe was resected six months AD because of
an aspergilloma.
ACT with CAPRI cells was begun after the tumor
resection (two months AD); the patient received 152 in-
jections of the CAPRI cells; during the first year, she
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Figure 2 Survival time and therapeutic modalities of a 62-year-old German Caucasian woman with non-small cell lung cancer. Shown
are months of survival after diagnosis and therapeutic modalities in chronological order. CAPRI, cascade primed immune; PET/CT, positron
emission tomography/computed tomography.
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sequently once a week.
The patient is in good condition and has survived for
the last 55 months (Figure 3).
Patient 4
Oncological diagnosis
The 77-year-old German Caucasian man presented with a
large cell undifferentiated pancoast tumor (IIIB, T3N3M0)
of the left upper lobe that infiltrated the lymph nodes, the
clavicle, the first rib and the plexus brachialis; no distant
metastasis was found. A PET/CT scan was performed
every three months in the first year AD, in the second year
every six months and subsequently each year. No 18F-FDG
uptake was seen in the examinations after surgery. Be-
fore the PET/CT scan, the CAPRI cell therapy had to be
interrupted for two weeks to avoid unspecific uptake of
18F-FDG by CAPRI cells in the tumor region.
Therapy
Over the course of five months, the patient received the
maximum radiation dose of 70Gy in combination with
25 rounds of cisplatin. In the subsequent surgery six
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Figure 3 Survival time and therapeutic modalities of a 75-year-old Ge
are months of survival after diagnosis and therapeutic modalities in chronoa portion of the pleura were resected, but it was not pos-
sible to remove the portions of the tumor that enveloped
the plexus brachialis.
ACT with 100 to 120 million CAPRI cells was admin-
istered every weekday until surgery, one third intracuta-
neously, two-thirds intravenously. Because the tumor
could not be completely removed, the CAPRI cell ther-
apy was continued for an entire year with the same
frequency and intensity. No negative side effects were
observed despite the large amounts of activated immune
cells. The patient received, in the first year, 223 injec-
tions of CAPRI cells; he still receives 20 to 40 million of
CAPRI cells one to two times per week, with interrup-
tions for excursions and other endeavors. For several
years after the surgery, the patient has enjoyed playing
golf and is still alive after 120 months (Figure 4).
Discussion
The therapy of patients with NSCLC in stages IIIB and
IV remains unsatisfactory, despite improvements with
combined radiation and chemotherapy and newer mo-
dalities. We report the successful adjuvant treatment
with the CAPRI cells for four patients in stages IIIB and
IV. All four patients surpassed the median survival time22 24 55
months
rman Caucasian woman with non-small cell lung cancer. Shown
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S = surgery: upper lobe, first rib, clavicle, part of the pleura
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Figure 4 Survival time and therapeutic modalities of a 77-year-old German Caucasian man with non-small cell lung cancer. Shown are
months of survival after diagnosis and therapeutic modalities in chronological order. CAPRI, cascade primed immune.
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39 months AD; the other patients have survived up to
the time of this publication 40, 55, and 120 months, re-
spectively. The patients reported that they were able to
resume their normal activities, such as long walks, bicyc-
ling or playing golf after they had received the CAPRI
cell injections (patients 2, 3 and 4). An adverse effect
was observed in patient 2 after the thoracic injection of
300 million CAPRI cells. She responded with fever and
tiredness for two days. The thoracic administration of
lower cell numbers, that is, 100 million CAPRI cells, was
well tolerated.
The preparation of CAPRI cells differs from other ACT
methods and has been previously described [4]. The im-
mune cells are isolated from the peripheral blood. The T
lymphocytes are activated in vitro with the monoclonal
antibody CD3, in the presence of other immune cells,
especially monocytes. The activated T lymphocytes stimu-
late monocytes to present the phagocytozed tumor mater-
ial. It is very important to add ‘new’ unstimulated T
lymphocytes to the stimulated monocytes because CD3-
activated T lymphocytes internalize the antigen-T-cell
receptor and cannot recognize the cancer-relevant infor-
mation of monocytes. Using proper timing in the activa-
tion steps yields the CAPRI cells after 24 hours. These
CAPRI cells recognize and destroy cancer cells and are
ready to be injected into patients. However, in the majority
of the cases, larger numbers of CAPRI cells are needed;
the CAPRI cells are cultured for one week. The addition
of the cytokine interleukin-2 induces cell division and an
increase in the number of CAPRI cells. The CAPRI cells
can be produced for cancer patients without loss of time
because no tumor-immunogenic peptides need to be iden-
tified, which must be inoculated into APC. Furthermore,
the T lymphocytes can be used from the peripheral blood
and can be easily expanded. The T lymphocytes from
the blood are not damaged by the tumor environmentas in the case of TIL. Finally, we have tested many dif-
ferent types of cancer and found that the monocytes of
other cancers also present tumor-immunogenic deter-
minants [4].
The point of time for isolating the immune cells for
the preparation of the CAPRI cells influences the effi-
ciency of the CAPRI cells. For the success of ACT, it is
important to isolate the immune cells before they are
damaged by radiation and chemotherapy. In patients 1
and 2, the immune cells were isolated after completion
of the first rounds of chemotherapy and radiation; that
is, the immune cells and/or their precursors in the bone
marrow were exposed to chemotherapeutical reagents
and/or radiation therapy. Another influential factor is
the presence of a large tumor mass; in patients 1 and 2,
the tumor could not be removed or reduced by surgery.
A larger tumor mass had to be attacked by the immune
cells. Understandably, it is not possible to derive strong
conclusions from four patients. We do not know whether
patient 1 would have survived longer if the immune cells
were isolated from his blood before chemotherapy. Al-
though patient 1 was the only one with distant metastasis,
it is worthy of note that the median survival of NSCLC pa-
tients with stage IV seems to differ only minimally from
patients with stage IIIB [5,6]. In patient 2 (stage IIIB),
chemotherapy and radiation preceded the immune cell
isolation. The tumor could not be resected. Although the
patient shows a prolonged survival time of 40 months
with a stabilization of the disease, including a marginal
tumor reduction, a local regrowth of the tumor was recog-
nized in the PET/CT scan in the 36th month. In contrast,
patient 3 (stage IIIB) and patient 4 (pancoast tumor) are
still in complete remission 55 and 120 months AD with-
out signs of recurrence. Patient 3 had decided to undergo
only surgery, in addition to the CAPRI cell therapy,
whereas patient 4 had a combined chemotherapy and ra-
diation but his CAPRI cells were prepared from immune
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therapy and radiation. With all of the caveats of immuno-
genetic variations among these patients, variations of
tumor size, tumor type and the total numbers of CAPRI
cells injected in these four patients, the disease course in
patients 3 and 4 suggests that there is an advantage in iso-
lating immune cells before chemotherapy and radiation.
Furthermore, the resection and reduction of the tumor, if
possible, seem to be advantageous in stages IIIB and IV.
Another aspect appears in patient 4. In the resected
tumor material, no living cancer cell was found after six
months, neither in the tumor itself nor in the clavicle,
rib or lymph nodes. This observation suggests a syner-
gism of chemotherapy and radiation with a simultaneous
CAPRI cell therapy. The halt of tumor growth by chemo-
therapy or radiation may support the downsizing of the
tumor by the CAPRI cells. Furthermore, the inflammation
caused by irradiation and chemotherapy may enhance mi-
gration to the tumor and the cytotoxic activity.Conclusions
Cancer cells of the NSCLC type appear to be excellent
immunogenic targets for the CAPRI cells. The inflam-
mation caused by chemotherapy and radiation may be
an additional stimulus for cytotoxic attacks by the CAPRI
cells. The reduction of the cancer mass by surgery or the
arrest of tumor growth by chemotherapy and radiation
seems to support the tumor downsizing by the CAPRI
cells. For the achievement of a synergism between the
CAPRI cells and other modalities, it is important to isolate
the immune cells before chemotherapy, radiation or other
treatment modalities, which might damage the bone mar-
row and the immune cells.Consent
Written informed consent was obtained from each of
the three surviving patients and from the wife of the de-
ceased patient for publication of this case series and any
accompanying images. A copy of the written consents are
available for review by the Editor-in-Chief of this journal.Ethical Approval
IRB approval was not required as, in Germany, treat-
ment attempts with new modalities are permitted, if they
are performed on the authority of the medical doctor
[4]. The authors hereby confirm that the treatment was
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the discretion of the responsible physician (RW). Con-
firmation of this is available for the Editor in Chief of
the journal to check.
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